Aspen Pharmacare Holdings Ltd
OTC:APNHY
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| ZA |
A
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
48.8B ZAR |
Loading...
|
|
| ZA |
B
|
Bidvest Group Ltd
JSE:BVT
|
82.1B ZAR |
Loading...
|
|
| IL |
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
126.1B ILS |
Loading...
|
|
| IN |
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
1T INR |
Loading...
|
|
| IE |
|
Perrigo Company PLC
NYSE:PRGO
|
2B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
282.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
226B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.5B GBP |
Loading...
|
Market Distribution
| Min | -2.8% |
| 30th Percentile | 2.2% |
| Median | 17.3% |
| 70th Percentile | 38% |
| Max | 468.2% |
Other Profitability Ratios
Aspen Pharmacare Holdings Ltd
Glance View
In the vibrant world of global pharmaceuticals, Aspen Pharmacare Holdings Ltd. stands out as a beacon of South African innovation and business acumen. Founded in Durban in 1997, Aspen has grown from modest beginnings into a multinational powerhouse. The company’s core strength lies in manufacturing and producing a diversified portfolio of pharmaceutical products, including generic medications, branded pharmaceuticals, and over-the-counter consumer health products. It further engages in anesthetics, nutritional products, and critical care drugs, offering solutions to myriad health challenges across more than 50 countries. This diversification not only ensures a broad market appeal but effectively hedges against the risks inherent in the pharmaceutical sector, such as patent expirations and regulatory hurdles. Aspen’s financial blueprint is designed around strategic partnerships and manufacturing competencies that serve both developed and emerging markets. It generates revenue primarily through its extensive distribution network and its ability to produce cost-effective generics that address high-demand therapeutic areas, such as cardiovascular, diabetes, and cancer treatments. The company’s growth is fuelled by both organic expansion and astute acquisitions, such as the incorporation of select portfolios from global giants like GlaxoSmithKline. Aspen meticulously balances manufacturing efficiency with stringent regulatory compliance, operated through state-of-the-art facilities accredited by international regulatory bodies. By maintaining this commitment to quality and cost-efficiency, Aspen differentiates itself from competitors and consolidates its position as a significant player in the global pharmaceutical landscape.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Aspen Pharmacare Holdings Ltd is 17.3%, which is below its 3-year median of 18.7%.
Over the last 3 years, Aspen Pharmacare Holdings Ltd’s Operating Margin has decreased from 25.5% to 17.3%. During this period, it reached a low of 16.2% on Dec 31, 2024 and a high of 25.5% on May 30, 2022.